ABIONYX Pharma SA (EPA:ABNX)

France flag France · Delayed Price · Currency is EUR
3.540
-0.050 (-1.39%)
Apr 28, 2026, 5:35 PM CET
190.16%
Market Cap 124.88M
Revenue (ttm) 4.10M
Net Income (ttm) -5.50M
Shares Out 35.28M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 63,516
Average Volume 136,149
Open 3.550
Previous Close 3.590
Day's Range 3.505 - 3.630
52-Week Range 1.146 - 5.290
Beta 0.67
RSI 47.32
Earnings Date Sep 24, 2026

About ABIONYX Pharma

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 51
Stock Exchange Euronext Paris
Ticker Symbol ABNX
Full Company Profile

Financial Performance

In 2025, ABIONYX Pharma's revenue was 4.10 million, a decrease of -9.91% compared to the previous year's 4.55 million. Losses were -5.50 million, 25.5% more than in 2024.

Financial Statements

News

There is no news available yet.